International Journal of Nanomedicine
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Nano-liposomal dry powder inhaler of tacrolimus: Preparation, characterization, and pulmonary pharmacokinetics
(7349) Total Article Views
Authors: Mahavir Chougule, Bijay Padhi, Ambikanandan Misra
Published Date January 2007
Volume 2007:2(4) Pages 675 - 688
Mahavir Chougule, Bijay Padhi, Ambikanandan Misra
TIFAC-CORE in NDDS, Pharmacy Department, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Kalabhavan, Vadodara, India
Abstract: The studies were undertaken to evaluate feasibility of pulmonary delivery of liposomaly encapsulated tacrolimus dry powder inhaler for prolonged drug retention in lungs as rescue therapy to prevent refractory rejection of lungs after transplantation. Tacrolimus encapsulated liposomes were prepared by thin film evaporation technique and liposomal dispersion was passed through high pressure homogenizer. Tacrolimus nano-liposomes (NLs) were separated by centrifugation and characterized. NLs were dispersed in phosphate buffer saline (PBS) pH 7.4 containing different additives like lactose, sucrose, and trehalose, and L-leucine as antiadherent. The dispersion was spray dried and spray dried powders were characterized. In vitro and in vivo pulmonary deposition was performed using Andersen Cascade Impactor and intratracheal instillation in rats respectively. NLs were found to have average size of 140 nm, 96% ± 1.5% drug entrapment, and zeta potential of 1.107 mV. Trehalose based formulation was found to have low density, good flowability, particle size of 9.46 ± 0.8 µm, maximum fine particle fraction (FPF) of 71.1 ± 2.5%, mean mass aerodynamic diameter (MMAD) 2.2 ± 0.1 µm, and geometric standard deviation (GSD) 1.7 ± 0.2. Developed formulations were found to have in vitro prolonged drug release up to 18 hours, following Higuchi’s Controlled Release model. In vivo studies revealed maximal residence of tacrolimus within lungs of 24 hours, suggesting slow clearance from the lungs. The investigation provides a practical approach for direct delivery of tacrolimus encapsulated in NLs for controlled and prolonged retention at the site of action. It may play a promising role as rescue therapy in reducing the risk of acute rejection and chronic rejection.
Keywords: lung transplant rejection, tacrolimus, nano-liposomes, spray drying, dry powder inhaler
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- ASNM conference 2014
Join us at the American Society for Nanomedicine Conference in Maryland, March 28th - 30th 2014.
- Impact Factors
- Have an opinion about one of our articles?
We encourage you to write a letter to the editor.
- Interested in being a peer-reviewer?
Click here to register.
- MLA'14 -
May 16–21, 2014
Authors are welcome to send an abstract or draft manuscript to obtain a view from the Editor about the suitability of their paper. Please email here and include which journal you are interested in submitting your manuscript to. Our Editors will do a quick review of your paper and advise if they believe it is appropriate for submission to their journal.
- Formulation and evaluation of drug-loaded targeted magnetic microspheres for cancer therapy
- Intracellular heavy metal nanoparticle storage: progressive accumulation within lymph nodes with transformation from chronic inflammation to malignancy
- Applications of gold nanoparticles in cancer nanotechnology
- Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer